Predisposition To, Prognosis For And Treatment Of Breast Cancer Relating To Human Chromosome 16

Abstract

The present invention relates to methods and kits based on the presence or absence of the c-mip gene located on the human chromosome 16, wherein reduced amounts of c-mip gene, transcriptional product, or translational product is indicative of a period of metastasis-free, recurrence-free and/or disease-free survival in an individual suffering from breast cancer. The invention, thus, relates to methods for the detection of predisposition to and/or for determining the prognosis for a period of metastasis-free, recurrence-free and/or disease-free survival of individuals suffering from breast cancer. Furthermore, the present invention pertains to a method for determining the treatment regime of an individual suffering from breast cancer as well as methods for classification of at least one tumour from an individual suffering from breast cancer. In addition, the invention pertains to kits for use in the methods.


Claims

Download Citation


Sign in to the Lens

Feedback